Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Cardiology
|
| gptkbp:approves |
gptkb:1985
gptkb:FDA |
| gptkbp:available_on |
gptkb:tablet
injection |
| gptkbp:brand |
gptkb:Cordarone
gptkb:Pacerone |
| gptkbp:casnumber |
81161-70-0
|
| gptkbp:chemical_formula |
C25 H29 I2 N
|
| gptkbp:class |
benzofuran derivative
|
| gptkbp:clinical_trial |
gptkb:AF-CHF_trial
AF-CHF study AMIO-CAD trial Atrial Fibrillation Follow-up Study Ventricular Tachycardia Study |
| gptkbp:contraindication |
cardiogenic shock
second or third degree AV block severe sinus node dysfunction |
| gptkbp:developed_by |
gptkb:Wyeth_Pharmaceuticals
|
| gptkbp:dosage_form |
oral tablet
200 mg daily 400 mg daily intravenous solution loading dose of 800-1600 mg |
| gptkbp:excretion |
urine
bile |
| https://www.w3.org/2000/01/rdf-schema#label |
Amiodarone
|
| gptkbp:interacts_with |
gptkb:fruit
gptkb:digoxin gptkb:warfarin statins |
| gptkbp:lifespan |
15-100 days
|
| gptkbp:mechanism_of_action |
blocks sodium channels
blocks calcium channels blocks potassium channels |
| gptkbp:metabolism |
hepatic
|
| gptkbp:route_of_administration |
oral
intravenous |
| gptkbp:side_effect |
liver toxicity
thyroid dysfunction skin discoloration pulmonary toxicity |
| gptkbp:storage |
room temperature
protected from light |
| gptkbp:used_for |
treatment of atrial fibrillation
treatment of atrial flutter treatment of ventricular tachycardia |
| gptkbp:bfsParent |
gptkb:Mavyret
|
| gptkbp:bfsLayer |
6
|